Business Context and Reporting Period
This Form 8-K is a Current Report filed by AVRA Medical Robotics, Inc. (not SS Innovations International, Inc.) on March 9, 2021, covering events from March 1, 2020, through February 11, 2021. The company is an emerging growth company focused on surgical robotics and air sanitization devices. The filing details unregistered equity sales, changes in corporate governance, and executive compensation arrangements.
Key Financial Metrics and Capital Activities
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins). Instead, it reports specific capital raising and debt restructuring activities:
- Private Placements: Issued Units at $1.00 per Unit in three separate offerings (Nov 2020, Dec 2020, Jan 2021). Each Unit typically included 4 shares of common stock and a warrant to purchase 5 shares at $0.40.
- Debt Conversion: CEO Barry F. Cohen converted $202,700 in notes due to him into Units in December 2020.
- Debt Extension: Extended the maturity of $195,000 in notes owed to the CEO from Dec 31, 2020, to Dec 31, 2021.
- Investment: Invested $210,000 (cash and stock) in a subsidiary, Avra Air, LLC, acquiring a 49.8% interest.
Material Changes and Corporate Actions
Significant changes in equity structure and leadership occurred during the reporting period:
- Board and Officer Changes (Effective March 1, 2020):
- Peter Carnegie resigned as a director.
- Alen Sands York and Arthur Tomassetti were appointed as directors.
- Nikhil Shah, D.O., resigned as Chief Strategy Officer and was appointed Senior Strategy Advisor.
- Executive Compensation:
- CEO Barry F. Cohen's employment agreement was extended for four years (effective July 1, 2020), accompanied by an option to purchase 1,000,000 shares at $0.25.
- New directors and the Senior Strategy Advisor received stock options ranging from 36,000 to 108,000 shares, vesting over 36 months.
- Share Issuances: Issued shares for services rendered to consultants, advisors, and the Chief Medical Officer, totaling over 1.3 million shares in November 2020 alone.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking financial guidance or a formal risk factor section. However, the following items indicate operational focus and potential contingencies:
- Strategic Focus: The company is actively developing surgical robotics and vehicular air sterilization technology (via Avra Air, LLC).
- Royalty Obligations: AVRA agreed to pay Avra Air a royalty of $1.50 per vehicular air sterilization kit sold for two years.
- Liquidity Strategy: The company relies heavily on private placements to accredited investors and debt-to-equity conversions to fund operations, suggesting limited access to public capital markets.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants following the multiple private placements and service issuances described.
- Confirm the current status of the $195,000 note extension and the $202,700 note conversion with the CEO.
- Review the development stage and commercialization timeline of Avra Air, LLC, given the royalty obligations and equity investment.
- Check for any subsequent filings regarding the vesting schedules of the new director and executive stock options.
- Validate the company's cash position, as the filing indicates reliance on private funding rather than operating revenue.